GenomeDx’s Decipher GRID and Decipher Biopsy to be Featured at the 31st Annual EAU Congress

San Diego – March 7, 2016 – GenomeDx Biosciences today announced that three abstracts featuring Decipher GRID (Genomics Resource Information Database) and Decipher Prostate Cancer Classifier tests will be presented at the 31st Annual EAU Congress (EAU16) held March 11-15 in Munich, Germany. The Annual EAU Congress is Europe’s largest urological event showcasing the latest […]

New Study Demonstrates that GenomeDx’s Decipher™ Test was Superior to Current Risk Assessment Tools in Predicting Metastatic Prostate Cancer

Data Presented by at 2013 American Urological Association Annual Meeting San Diego, May 8, 2013 – GenomeDx Biosciences today announced the presentation of results of an independent validation study demonstrating that Decipher™ was a better predictor of clinical metastasis in prostate cancer patients treated with surgery than current risk assessment tools, including preoperative PSA levels, […]

New Study Shows that Genetic Information from Prostate Needle Biopsy May Be Used to Predict Tumor Aggressiveness – GenomeDx

Study published in Journal of Molecular Diagnostics shows concordance in molecular information between prostate biopsy and surgery samples analyzed with the Decipher Prostate Cancer Classifier San Diego, March 15, 2016 – GenomeDx Biosciences today announced results from a new study which demonstrates the ability to measure and evaluate biomarkers from RNA expression data obtained from […]

GenomeDx and Bostwick Laboratories Announce Marketing Agreement for Decipher Prostate Cancer Classifier Test

San Diego, CA, Uniondale, NY, October 4, 2016 – GenomeDx Biosciences and Bostwick Laboratories, Inc. today announced that Bostwick has entered into a marketing partnership agreement with GenomeDx, provider of the genomic Decipher® Prostate Cancer Classifier tests for men diagnosed with localized prostate cancer. Bostwick Laboratories is a national, full-service laboratory specializing in uropathology, and […]

GenomeDx and Mayo Clinic Enter Agreement to Conduct Validation Study of Decipher® Prostate Cancer Test in Patients Receiving Biopsy Prior to Treatment

Builds on initial collaboration with Mayo Clinic that led to the development and commercialization of Decipher in patients following prostate surgery SAN DIEGO – November 11, 2014 – GenomeDx Biosciences today announced that the company has expanded its research agreement with Mayo Clinic to initiate a validation study to expand the use of the Decipher® […]

Decipher® Predicts Metastasis and Identifies Biomarkers Predictive of Aggressive Disease in African American Men

Study published by the Journal of Clinical Oncology provides biomarker insights into racial disparity in prostate cancer outcomes & shows that Decipher successfully stratifies African American men for metastasis San Diego, August 4, 2015 – GenomeDx Biosciences announced today that its commercially-available Decipher® testing platform identified, with statistical significance, a set of prostate cancer biomarkers […]

Cedars-Sinai to Join Decipher GRID through Partnership with GenomeDx

Cedars-Sinai signs on to test prostate cancer patients with Decipher Prostate Cancer Classifier under innovative data sharing program between physicians from leading cancer centers San Diego, October 13, 2015 – GenomeDx Biosciences today announced that Cedars-Sinai has partnered with the company on the Decipher® Genomics Resource Information Database (Decipher GRIDTM), a clinical genomics data sharing […]

Centers for Medicare and Medicaid Services Publishes Draft Coverage Decision to Reimburse the Decipher® Test for Intermediate & High Risk Prostate Cancer

San Diego, CA – Oct. 16, 2014 – GenomeDx Biosciences today announced that a draft local coverage determination (LCD) for its Decipher® Prostate Cancer Classifier has been published by the Centers for Medicare and Medicaid Services (CMS) describing a coverage and payment policy for use of the Decipher test in men who have undergone radical […]

GenomeDx Adds a National PPO to Make Available Decipher® Prostate Cancer Test

San Diego, September 25, 2014 – GenomeDx Biosciences today announced that it has entered into a contractual agreement with MultiPlan, Inc. for diagnostic laboratory testing. The agreement includes GenomeDx Biosciences’ participation in the MultiPlan Network, expanding access to the Decipher® Prostate Cancer Classifier to health plan members who access the more than 500,000 providers participating […]